Press release
Diabetic Gastroparesis Clinical Trials Analysis 2025: Prokinetic Agents, Ghrelin Agonists, and Neuromodulators Target Gastric Motility Restoration and Symptom Relief | DelveInsight
Diabetic Gastroparesis Clinical Trials Analysis
Current trials explore 5-HT4 receptor agonists, ghrelin receptor agonists, and selective dopamine D2/D3 antagonists aimed at improving motility and reducing nausea, bloating, and early satiety. Notably, relamorelin and metoclopramide analogs continue advancing through pivotal evaluation, while novel approaches such as vagal nerve stimulation and gastric peroral endoscopic myotomy (G-POEM) are being tested for refractory cases.
Primary endpoints across ongoing phase II-III studies include gastric emptying rate, Gastroparesis Cardinal Symptom Index (GCSI), and patient-reported quality-of-life outcomes. With multiple agents nearing registration milestones, the next few years may bring the first wave of differentiated therapies addressing both the symptomatic and physiological burdens of diabetic gastroparesis.
Interested in learning more about the current treatment landscape and the key drivers shaping the diabetic gastroparesis pipeline? Click here: https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Diabetic Gastroparesis Pipeline Report
• DelveInsight's diabetic gastroparesis pipeline analysis depicts a strong space with 6+ active players working to develop 8+ pipeline drugs for diabetic gastroparesis treatment.
• The leading diabetic gastroparesis companies include Neurogastrx, Vanda Pharmaceuticals, Takeda, Processa Pharmaceuticals, Theravance Biopharma, and others are evaluating their lead assets to improve the diabetic gastroparesis treatment landscape.
• Key diabetic gastroparesis pipeline therapies in various stages of development include TD 1473, NG101, PCS-12852, THRX-149699, Camicinal, and others.
• In June 2025, Atmo Biosciences received FDA 510(k) clearance for its Atmo Gas Capsule System, allowing U.S. marketing and sales. The capsule aids in diagnosing gut motility disorders like gastroparesis and slow transit constipation. Clearance was based on positive results from a multi-site pivotal clinical study meeting all endpoints.
• In April 2025, Vanda Pharmaceuticals accused the FDA of deliberately delaying its request for a hearing on tradipitant's approvability for gastroparesis, blaming internal bureaucracy and recent leadership changes, including the appointment of Commissioner Dr. Martin Makary and agency staffing cuts.
• In January 2025, Vanda Pharmaceuticals accepted the FDA's hearing for the NDA of Tradipitant for gastroparesis, a digestive disorder with no new FDA-approved treatments in over 40 years. Current therapies are often ineffective, and studying new drugs is difficult due to symptom variability and placebo effects.
Request a sample and discover the recent breakthroughs happening in the diabetic gastroparesis pipeline landscape @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Diabetic Gastroparesis Overview
Diabetic gastroparesis is a complication of diabetes that affects the stomach's ability to empty properly due to nerve damage, particularly to the vagus nerve. This delayed gastric emptying leads to symptoms such as nausea, vomiting, bloating, early satiety, and abdominal pain. It can cause poor blood sugar control because food digestion becomes unpredictable. Diagnosis typically involves gastric emptying studies and symptom evaluation. Management focuses on controlling blood glucose levels, dietary modifications, and medications to stimulate stomach motility or reduce symptoms. In severe cases, more advanced treatments or surgical options may be considered.
Find out more about diabetic gastroparesis medication @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Diabetic Gastroparesis Treatment Analysis: Drug Profile
PCS-12852: Processa Pharmaceuticals
PCS-12852 is an innovative, highly selective 5-HT4 receptor agonist designed to treat gastrointestinal (GI) motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia, and gastroparesis. The drug is currently undergoing Phase II clinical trials for the treatment of Diabetic Gastroparesis.
NG101: Neurogastrx
NG101 is a potent and selective dopamine D2 receptor antagonist that is peripherally restricted. It is in Phase II clinical trials for treating Diabetic Gastroparesis. Preclinical studies from Neurogastrx have demonstrated that, in addition to its strong antiemetic effects, NG101 is also expected to significantly enhance gastric motility, making it a promising candidate for gastroparesis treatment.
Learn more about the novel and emerging diabetic gastroparesis pipeline therapies @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Diabetic Gastroparesis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Scope of the Diabetic Gastroparesis Pipeline Report
• Coverage: Global
• Key Diabetic Gastroparesis Companies: Neurogastrx, Vanda Pharmaceuticals, Takeda, Processa Pharmaceuticals, Theravance Biopharma, and others.
• Key Diabetic Gastroparesis Pipeline Therapies: TD 1473, NG101, PCS-12852, THRX-149699, Camicinal, and others.
Dive deep into rich insights for drugs used for diabetic gastroparesis treatment; visit @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Diabetic Gastroparesis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Diabetic Gastroparesis Pipeline Therapeutics
6. Diabetic Gastroparesis Pipeline: Late-Stage Products (Phase III)
7. Diabetic Gastroparesis Pipeline: Mid-Stage Products (Phase II)
8. Diabetic Gastroparesis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading market research and business consulting firm specializing in the life sciences industry. We provide pharmaceutical companies with tailored, end-to-end solutions to optimize their strategies and enhance business outcomes. With our subscription-based platform, PharmDelve, you can access a comprehensive range of healthcare and pharma market research reports, ensuring informed decision-making and sustained growth.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Gastroparesis Clinical Trials Analysis 2025: Prokinetic Agents, Ghrelin Agonists, and Neuromodulators Target Gastric Motility Restoration and Symptom Relief | DelveInsight here
News-ID: 4212273 • Views: …
More Releases from DelveInsight
Spinal Implants Market Size Report 2032: Market Porter's Five Forces Analysis, M …
DelveInsight's Spinal Implants Market Insights Report 2032 provides the current and forecast market analysis, individual leading Spinal Implants Companies market shares, challenges, Spinal Implants Market Drivers, barriers, trends, and key market Spinal Implants companies in the market.
To read more about the latest highlights related to the Spinal Implants Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/spinal-implants-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Spinal…
Genome Editing Market Size Report 2032: Market Porter's Five Forces Analysis, Ma …
DelveInsight's Genome Editing Market Insights Report 2032 provides the current and forecast market analysis, individual leading Genome Editing Companies market shares, challenges, Genome Editing Market Drivers, barriers, trends, and key market Genome Editing companies in the market.
To read more about the latest highlights related to the Genome Editing Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/genome-editing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Genome Editing Market…
Retinopathy of Prematurity Therapeutics Market: Early-Stage Pipeline and FDA Des …
The Retinopathy of Prematurity treatment market is expected to witness significant growth in the coming years, primarily driven by advancements in diagnostic technologies and the development of novel therapeutics by key players such as Novartis, Regeneron, Bayer, FeliQS Corporation, and Infant Bacterial Therapeutics, among others. This growth trajectory is further supported by the rising awareness about Retinopathy of Prematurity management, improvements in neonatal care units, and increasing focus on preventive…
Chronic Kidney Disease Market Evolution: Novel Drugs, AI Integration, and Combin …
The chronic kidney disease (CKD) treatment market is witnessing robust expansion across the 7MM. This upward trajectory is primarily fueled by increasing disease prevalence, growing aging populations, rising diabetes and hypertension cases, and the emergence of innovative therapies from key chronic kidney disease players including AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Vifor Pharma, Otsuka Pharmaceutical, Reata Pharmaceuticals, Akebia Therapeutics, and Kyowa Kirin, among others, who are actively advancing the CKD…
More Releases for Gas
City Gas Distribution Market 2022 key developmental strategies implemented by th …
The City Gas Distribution report is an in-depth examination of the global City Gas Distribution's general consumption structure, development trends, sales techniques, and top nations' sales. The research looks at well-known providers in the global City Gas Distribution industry, as well as market segmentation, competition, and the macroeconomic climate. A complete City Gas Distribution analysis takes into account a number of aspects, including a country's population and business cycles, as…
Know about City Gas Distribution Market Growth with Top Companies details like: …
The City Gas Distribution Market 2020-2024 Report involve of strong research on global City Gas Distribution industry which enables the customer to look at the possible requirement as well as prediction. The constraints and drivers are assembled after a significant study of the global City Gas Distribution market's proficiency. The development ratio which is expected in perspective of the rational analysis provides thorough information of the worldwide City Gas Distribution…
City Gas Distribution Market 2019: Top Companies- Gujarat Gas, Indraprastha Gas, …
A network that deliver the gas in the city. Growth in the market is anticipated on account of increasing natural gas demand from domestic, commercial, industrial as well as automotive end user segments.
Get Sample Copy of This Report at https://www.orianresearch.com/request-sample/1011059
City Gas Distribution Industry 2019 Global Market research report provides a detailed analysis of market growth factors, industry share, regional trends, size and Forecast till 2025. This report…
City Gas Distribution Market Exploring Future Growth 2019-2023 and Key Players - …
Global City Gas Distribution Market Research Report consists of all the significant data related to the global market. The report presents a comprehensive analysis of the various industry growth factors, including the market trends, dynamics, estimates, production and consumption ratio, industry development factors, size, share, supply and demand, forecast trends, sales, as well as several other factors. The report has been generated leveraging a blend of the primary and secondary…
Global City Gas Distribution Market 2018: Key Players – Gujarat Gas, Indrapras …
Summary
WiseGuyReports.com adds “City Gas Distribution Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023” reports to its database.
This report provides in depth study of “City Gas Distribution Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The City Gas Distribution Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an…
City Gas Distribution Market Latest Technology Trends 2018 | Growth by Top Compa …
A network that deliver the gas in the city.
Growth in the market is anticipated on account of increasing natural gas demand from domestic, commercial, industrial as well as automotive end user segments.
The report Global City Gas Distribution Market 2018 focuses on fundamental know-how of City Gas Distribution segment. The report provides comprehensive study and vivid description of drivers, limitations, openings, request factors, market size, conjectures, and patterns in the Worldwide…
